Reid Hoffman weighs in on the ‘tokenmaxxing’ debate
Reid Hoffman says tracking AI token use can gauge adoption, but cautions it should be paired with context and not treated as a direct productivity metric.
Reid Hoffman says tracking AI token use can gauge adoption, but cautions it should be paired with context and not treated as a direct productivity metric.
After a very profitable decade on Microsoft’s board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.
The neolab is betting that automating routine computer tasks will soon outpace coding as AI’s biggest use case.